Products with Anti-Atherosclerotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3866 | 6''-O-Acetylglycitin |
| 1. 6''-O-Acetylglycitin is a potential nutriceutical. | |
| BCN3890 | Campestanol |
| 1. Campestanol, which shares the same basic structure and intestinal absorption pathway with cholesterol, does not accumulate when fed, and may be incorporated into the diet to block cholesterol absorption. | |
| BCN4049 | Nagilactone B |
| 1. Selective LXR activation in macrophages with nagilactone B induces ABCA1- and ABCG1-mediated cholesterol efflux while exerting minimal effects on lipogenesis and lipid accumulation in liver, resulting in regression of atherosclerosis, and therefore might be a promising strategy for therapeutics. | |
| BCN4349 | Momordicoside G |
| 1. Momordicosides K and L, the main bitter taste triterpene glycosides in Bitter melon; and bitter melon has been reported to have hypoglycemic, anti atherogenic and anti HIV activities. | |
| BCN4385 | Rutaecarpine |
| Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells. | |
